Homologous PRP vs Placebo in Knee Osteoarthritis in Over 65 Years Old Patients

Launched by ISTITUTO ORTOPEDICO RIZZOLI · May 24, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at the effectiveness of a treatment called Homologous Platelet-Rich Plasma (PRP) for knee osteoarthritis in patients over 65 years old. The study aims to compare the results of a single injection of Homologous PRP with a placebo (a harmless saline solution) over a period of six months. This will help researchers understand if the PRP treatment can improve knee function and reduce pain better than the placebo.

To participate, individuals must have knee osteoarthritis that affects only one knee and show signs of cartilage degeneration through imaging tests like X-rays or MRIs. Participants should also be able to actively take part in follow-up visits and provide written consent. However, certain individuals are not eligible, including those who have had knee surgery in the past year, have certain serious health conditions, or have a body mass index (BMI) over 35. If you join the trial, you can expect regular check-ups to assess your knee health and any changes in your symptoms during the study period.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Unilateral involvement;
• • 2. Signs and symptoms of degenerative pathology of the knee cartilage;
• • 3. Radiographic or MRI signs of degenerative pathology of the knee cartilage (Kellgren-Lawrence 1-4 grades);
• • 4. Ability and consent of patients to actively participate in clinical follow-up;
• • 5. Signature of informed consent
• Exclusion Criteria:
• • 1. Patients undergoing knee surgery within the previous 12 months;
• • 2. Patients with malignant neoplasms;
• • 3. Patients with rheumatic diseases;
• • 4. Patients with diabetes;
• • 5. Patients with hematologic diseases (coagulopathies);
• • 6. Patients with metabolic disorders of the thyroid gland;
• • 7. Patients abusing alcoholic beverages, drugs or medications
• • 8. Body Mass Index \> 35